Imagine cracking open your medicine cabinet and realizing the same antihistamine clearing your seasonal allergies might one day help you live longer. That scenario isn't as far-fetched as it sounds, thanks to researchers at Northeastern University who are mapping the genetic geography of aging itself—and finding that the drugs already sitting on pharmacy shelves could be the key to slowing down time.
The team, led by Albert-László Barabási, Distinguished University Professor of Physics at Northeastern, has developed a method for identifying which existing medications could be repurposed to target the biological processes of aging. Their research, published in Nature Aging in collaboration with scientists at Harvard, takes a novel approach: instead of starting from scratch with new drug development, they ask what the 6,442 already-approved drugs in the DrugBank database might accomplish if aimed at the right genetic targets.
The work hinges on understanding how aging genes organize themselves within the body. The researchers began with 1,250 genes from the Open Genes database known to be associated with aging, then mapped them onto the human interactome—a vast network of more than 500,000 protein interactions that represent where most drugs actually take effect. What they discovered was striking: aging genes aren't scattered randomly across this biological landscape. They cluster in specific neighborhoods, forming distinct modules around what scientists call the "hallmarks of aging," which include epigenetic alterations that control gene activity and mitochondrial dysfunction that impairs cellular energy production.
"If the genes were spread randomly, there is no way for a drug to specifically affect it because it's spread all over," said Bnaya Gross, a postdoctoral researcher in Barabási's lab and lead author of the study. "Our discovery is that aging genes are located in very specific areas, a very specific neighborhood, allowing you to find drugs that affect this neighborhood."
This finding transforms the challenge from an impossible needle-in-a-haystack search into a targeted map-reading exercise. Because aging genes occupy these discrete modules, researchers can now score any drug by how closely its protein targets cluster near these aging neighborhoods, and predict whether it would help reverse or accelerate aging processes.
For Barabási, whose own hair has turned gray with time, the personal stakes are tangible. "The challenge is figuring out which drugs are worth testing," he said. Repurposing existing medications offers a practical shortcut: these drugs have already cleared safety hurdles, making the path from laboratory discovery to actual treatment potentially faster and less expensive than starting from zero.
The approach marks a shift from chasing the mythical solutions of centuries past—Fountain of Youth legends and quick-fix wellness trends—toward a rigorous, network-based science of aging. With the genetic map now drawn, the next phase is testing which drugs, already proven safe in humans, might gently nudge the aging process in a healthier direction. It's a prospect that makes growing older feel less like an inevitability to surrender to, and more like a system waiting to be understood.